Response to Letter to the Editor: Comment on “Anticancer Drugs Associated With Tumor Lysis Syndrome: Insights From the US Food and Drug Administration Adverse Event Reporting System”.

HOME
>
論文・技術情報
>
Response to Letter to the Editor: Comment on “Anticancer Drugs Associated With Tumor Lysis Syndrome: Insights From the US Food and Drug Administration Adverse Event Reporting System”.

アブストラクト
ジャーナル名	Clinical therapeutics
Pubmed追加日	2026/6/5
投稿者	Wang, Wei; Dong, Zirui; Hong, Baoan; Bo, Yuxuan; Zhang, Xuezhou; Guan, Xin; Miao, Qi; Zhang, Ning
組織名	Department of Urology, Beijing Anzhen Hospital, Capital Medical University,;Beijing, PR China.;Department of Urology, Union Hospital, Tongji Medical College, Huazhong;University of Science and Technology, Wuhan, Hubei, PR China.;Department of Nuclear Medicine, First Hospital of Shanxi Medical University,;Shanxi Medical University, Taiyuan, Shanxi, PR China.;Beijing, PR China. Electronic address: Azurology_zn@126.com.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/42242947/